The Oncology Insights Podcast - Dr. Maximilian Stahl: Precision AML Therapy | Ep. 13

In this episode of The Oncology Insights Podcast, Dr. Maximilian Stahl, Director of the Leukemia and Myeloid Malignancy Program at Yale Cancer Center, explains how acute myeloid leukemia care is becoming more precise. He discusses molecular testing, induction therapy selection, targeted agents, transplant decisions, APL advances, and early phase trials for high-risk AML. Listen now on all major platforms!

What you’ll learn:

• AML testing strategy
• Targeted treatment selection
• Transplant decision-making
• APL therapy progress
• High-risk trial design

Meet the guest:

Dr. Maximilian Stahl is Director of the Leukemia and Myeloid Malignancy Program at Yale Cancer Center and Assistant Professor of Medicine at Yale School of Medicine. His work focuses on acute leukemia, early phase clinical trials, targeted therapy, measurable residual disease, and drug development for high-risk AML. Learn more from Dr. Maximilian Stahl on The Oncology Insights Podcast, available on all major platforms.

Liked this one? Don’t stop now. Here’s what we think you’ll love!